102735-88-6Relevant articles and documents
QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS
-
Paragraph 0087; 0088, (2018/12/04)
Disclosed are a quinazolinone derivative, a preparation method therefor, a pharmaceutical composition, and applications. Provided are a compound represented by formula I, a pharmaceutically acceptable salt, a solvate, a crystal form, a eutectic crystal, a
Indazole compounds and application thereof to preparation of IDO inhibitors
-
Paragraph 0081; 0082; 0083; 0084, (2018/11/04)
The invention discloses indazole compounds as shown in a formula (i) or (II) which is described in the specification, and a preparation method thereof, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation,autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.
Indazole compounds containing nitrogen substituents, and application of same as IDO inhibitors
-
Paragraph 0048; 0049; 0050, (2018/11/03)
The invention discloses nitrogen substituent-containing indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application ofthe compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections relatedto cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.
MINERALOCORTICOID RECEPTOR ANTAGONISTS
-
Page/Page column 79, (2014/02/15)
The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiome
MINERALOCORTICOID RECEPTOR ANTAGONISTS
-
Page/Page column 74, (2012/08/07)
Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl
SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS
-
Page/Page column 153; 154, (2010/11/18)
The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).
Substituted 2-nitrobenzyltrichloroacetate esters for photodirected oligonucleotide detritylation in solid films
Serafinowski, Pawel J.,Garland, Peter B.
supporting information; experimental part, p. 3284 - 3291 (2009/02/05)
Oligonucleotide microarray fabrication by chemical synthesis using photoacid generators in solid films could have advantages over existing methods, but has not matched the accuracy of conventional synthesis where detritylation is performed with acid solut
INDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS
-
Page/Page column 27, (2008/12/07)
The present invention relates to indazole derivatives of the following formula I, which can be used as vanilloid receptor ligands, processes for their preparation, and their use in treating diseases, conditions and/or disorders modulated by vanilloid receptors. (I)
7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS
-
, (2008/06/13)
This invention involves involves the use of compounds having the following structure: STR1 wherein: (a) R is unsubstituted C 1-C. sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C 1-C 3 alkanyl or alkenyl; unsubstituted
7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2-ADRENOCEPTOR AGONISTS
-
, (2008/06/13)
The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: STR1 wherein: (a) R is unsubst